Physician profile
Eric Arthur Lorio
NPI 1730670431
$4,402.64
in general payments reported to CMS, 2019-2025
25 companies · $1,811 in 2025
The $1,811 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $284 · 2022: $428 · 2023: $528 · 2024: $1,351 · 2025: $1,811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,045 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,045.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $760.74 | 2024-2025 | |
| Janssen Biotech, INC. | $339.83 | 2024-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $334.84 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $245.49 | 2025 | Xifaxan |
| Ardelyx, INC. | $195.96 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $179.74 | 2024-2025 | |
| Celgene Corporation | $143.63 | 2024 | Zeposia |
| Celltrion USA INC. | $112.73 | 2024-2025 | Vegzelma |
| Pfizer INC. | $105.64 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $89.12 | 2024-2025 | Dupixent |
| Gilead Sciences, INC. | $81.21 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $78.18 | 2025 | Voquezna |
| Lilly USA, LLC | $66.51 | 2024-2025 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $63.94 | 2024-2025 | Iqirvo |
| Daiichi Sankyo INC. | $58.57 | 2024-2025 | Injectafer |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $43.79 | 2024 | Livmarli |
| Medtronic, INC. | $39.42 | 2024 | Endoflip |
| Braintree Laboratories, INC. | $37.49 | 2025 | Sutab, Suflave |
| Novo Nordisk INC | $36.51 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $33.73 | 2025 | Zenpep |
| Alnylam Pharmaceuticals INC. | $27.87 | 2025 | Givlaari |
| Blueprint Medicines Corporation | $21.71 | 2024 | Ayvakit |
| Capsovision, INC. | $18.57 | 2024 | Capsocam Plus |
| Fujifilm Healthcare Americas Corporation | $14.48 | 2025 | |
| Intercept Pharmaceuticals, INC. | $14.30 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lorio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.